The purpose of the Clinical Research Office (CRO) is to provide central management and oversight functions for coordinating, facilitating, and reporting on the cancer clinical research of the center, whatever the origin. The CRO accomplishes this purpose by providing the following services to Mayo Clinic Cancer Center (MCCC) investigators: 1) Protocol development and maintenance support, 2) Regulatory support, 3) Data systems management, 4) Quality control, 5) Operational support, and 6) Information systems. With centralized services, the CRO provides a stable and efficient administrative structure to coordinate these activities across the entire scope of the MCCC, including phase I-III clinical trials, pilot studies, and population-based studies. The Clinical Research Office previously functioned as part of the Mayo Clinic Cancer Center Statistics Unit Shared Resource. This shared resource was comprised of two units - the Statistics Unit and the Research Support Services Unit. Due to the recent significant expansion in scope and increase in regulatory burden, the two units have now separated, forming the Biostatistics Shared Resource and the Clinical Research Office. The CRO supports clinical trials and non-interventional population-based clinical research that are supported by one or more of the following: ? Peer-reviewed extramural funds (NIH, DoD, etc.), ? Mayo Clinic Cancer Center (including CCSG) ? Phase land Phase II (NCI, U01, N01) ? NCI Cooperative Group and CCOP Programs (MCCC is the research base of the North Central Cancer Treatment Group (NCCTG) and a member of ECOG, RTOG, GOG, ACoSOG, and COG) ? Industry funds The ability to use the same database for all studies and to configure tables, interfaces, and reports to meet program or protocol specific needs, allows the systems and procedures to be consistent between all sponsors and programs. This consistency fosters efficiency and programmatic operational synergy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-30
Application #
6990026
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-15
Project End
2009-02-28
Budget Start
2004-09-15
Budget End
2005-02-28
Support Year
30
Fiscal Year
2004
Total Cost
$358,497
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567

Showing the most recent 10 out of 1129 publications